These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22030265)

  • 1. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
    Gomez-Lara J; Diletti R; Brugaletta S; Onuma Y; Farooq V; Thuesen L; McClean D; Koolen J; Ormiston JA; Windecker S; Whitbourn R; Dudek D; Dorange C; Veldhof S; Rapoza R; Regar E; Garcia-Garcia HM; Serruys PW
    EuroIntervention; 2012 Jun; 8(2):214-24. PubMed ID: 22030265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography.
    Gomez-Lara J; Radu M; Brugaletta S; Farooq V; Diletti R; Onuma Y; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Sep; 4(9):992-1001. PubMed ID: 21939939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study.
    Farooq V; Gomez-Lara J; Brugaletta S; Gogas BD; Garcìa-Garcìa HM; Onuma Y; van Geuns RJ; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):880-8. PubMed ID: 22514149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
    Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C
    JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
    Gomez-Lara J; Brugaletta S; Diletti R; Garg S; Onuma Y; Gogas BD; van Geuns RJ; Dorange C; Veldhof S; Rapoza R; Whitbourn R; Windecker S; Garcia-Garcia HM; Regar E; Serruys PW
    Eur Heart J; 2011 Feb; 32(3):294-304. PubMed ID: 21123276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
    Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.
    Gomez-Lara J; Garcia-Garcia HM; Onuma Y; Garg S; Regar E; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Dorange C; Veldhof S; Morel MA; de Vries T; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2010 Nov; 3(11):1190-8. PubMed ID: 21087756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100.
    Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM
    Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.
    Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R
    EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
    Serruys PW; Onuma Y; Garcia-Garcia HM; Muramatsu T; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Ormiston JA
    EuroIntervention; 2014 Mar; 9(11):1271-84. PubMed ID: 24291783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
    Diletti R; Karanasos A; Muramatsu T; Nakatani S; Van Mieghem NM; Onuma Y; Nauta ST; Ishibashi Y; Lenzen MJ; Ligthart J; Schultz C; Regar E; de Jaegere PP; Serruys PW; Zijlstra F; van Geuns RJ
    Eur Heart J; 2014 Mar; 35(12):777-86. PubMed ID: 24394380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial.
    Okamura T; Garg S; Gutiérrez-Chico JL; Shin ES; Onuma Y; García-García HM; Rapoza RJ; Sudhir K; Regar E; Serruys PW
    EuroIntervention; 2010 Apr; 5(8):932-8. PubMed ID: 20542778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
    Diletti R; Onuma Y; Farooq V; Gomez-Lara J; Brugaletta S; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Smits P; Koolen J; Meredith I; Li D; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    J Am Coll Cardiol; 2011 Jul; 58(3):258-64. PubMed ID: 21737016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification.
    Okamura T; Onuma Y; García-García HM; Regar E; Wykrzykowska JJ; Koolen J; Thuesen L; Windecker S; Whitbourn R; McClean DR; Ormiston JA; Serruys PW;
    JACC Cardiovasc Interv; 2010 Aug; 3(8):836-44. PubMed ID: 20723856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold.
    Gómez-Lara J; Brugaletta S; Diletti R; Gogas BD; Farooq V; Onuma Y; Gobbens P; Van Es GA; García-García HM; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):890-902. PubMed ID: 21523891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances.
    Mattesini A; Boeder N; Valente S; Löblich K; Dörr O; Secco GG; Foin N; Caiazzo G; Ghione M; Gensini GF; Porto I; Di Mario C; Nef H
    EuroIntervention; 2016 Aug; 12(5):e566-73. PubMed ID: 27497356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.
    Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.